DelveInsight

Mar 13, 2018

Anthera’s Sollpura flops after phase 3   Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the info...

Mar 12, 2018

Celiac Disease (Gluten-Sensitive Enteropathy) is a chronic, autoimmune, inflammatory disease of the small intestine characterized by damage to the lining of the small intestine and typically leads to dyspepsia, malabsorption and a variety of other symptoms. Individuals with Celiac Disease carry DQ2 or DQ8 MHC class ...

Mar 08, 2018

Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. The number of Diagnosed Prevalent Population of Transthyre...

Mar 06, 2018

Dermira pulling plug on acne drug after phase 3 failure Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after it failed to meet its primary endpoints in a pair of phase 3 trials. The drug was tested in patients aged nine and older with moderate to severe acne vulgaris. ...

Feb 22, 2018

Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual CAR-T therapies will yield sales of USD 1 billion, the investing companies...

Feb 22, 2018

Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the develo...

Feb 20, 2018

Rice University researchers tested CRISPR to cure sickle cell, now preparing for upcoming challenges A team of Researchers led by Rice University has recently tested CRISPR to correct the sickle cell mutation in up to 40% of the total stem cell samples taken from affected patients. Although the results are quite pro...

Feb 19, 2018

Immune checkpoints are the regulators of immune activation. They play a key role in maintaining immune homeostasis and preventing autoimmunity. Immune checkpoint activators are small molecules responsible for maintenance, modulation, and regulation of immune responses. Its significance in immune-therapeutics is back...

Feb 16, 2018

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...

Feb 14, 2018

Gilead Sciences has recently launched a highly effective hepatitis C drug Sovaldi at a whopping price of USD 84,000 per treatment course at the same time when ‘How to price a cure’ discussion has entered the pharma industry. Gilead bought a launch-ready drug and launched it very quietly hoping that it's very cost-ef...